OncoMatch/Clinical Trials/NCT06685718
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Is NCT06685718 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BG-60366 for non-small cell lung cancer.
Treatment: BG-60366 — This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NSCLC. The study will be conducted in 2 parts: 1) Phase 1a Dose Escalation and Safety Expansion, and 2) Phase 1b Dose Expansion.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR activating mutation
Required: EGFR c797s
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: third-generation EGFR tyrosine kinase inhibitor — advanced or metastatic
Disease progression on prior third-generation EGFR-TKI for advanced or metastatic disease
Must have received: platinum-based chemotherapy — after EGFR-TKI
either progressed or ineligible for currently available standard-of-care treatment (eg, platinum-based chemotherapy) after EGFR-TKI treatment
Cannot have received: fourth-generation EGFR tyrosine kinase inhibitor
Prior treatment with fourth-generation EGFR-TKI
Cannot have received: CDAC/proteolysis-targeting chimeras (PROTAC) compounds targeting EGFR mutations
other CDAC/proteolysis-targeting chimeras (PROTAC) compounds targeting EGFR mutations
Cannot have received: other drugs with the mechanism of action specifically targeting EGFR resistance mutations
Exception: except for the first- to third-generation EGFR-TKIs
other drugs with the mechanism of action specifically targeting EGFR resistance mutations (eg, C797X) (except for the first- to third-generation EGFR-TKIs)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado · Denver, Colorado
- Dana Farber Cancer Institute · Boston, Massachusetts
- Washington University School of Medicine Siteman Cancer Center · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center Mskcc · New York, New York
- Ohio State University · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify